| 标题 |
Fixed-duration ibrutinib-venetoclax with MRD-guided ibrutinib-obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trial |
| 网址 | |
| DOI | |
| 其它 |
期刊:The Lancet. Haematology 作者:Kater AP; Kersting S; Dubois JM; van der Holt B; da Cunha-Bang C; et al 出版日期:2025/12/01 |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)